• TTP Team is a eminent engineering company that specialize in biotech and pharmaceutical business
• The corporate serves blue-chip shoppers in Europe 
• TTP Team employs 1,000 folk throughout 27 places underneath the operational manufacturers Pharmaplan and Triplan
• Exyte CEO Büchele: “With the acquisition of TTP, Exyte expands its position as a global player in the pharma market, strengthening its footprint in Europe.”

STUTTGART, Germany, Sept. 5, 2024 /PRNewswire/ — Exyte, an international chief within the design, engineering, and supply of high-tech amenities, intends to obtain TTP Team (“TTP”), a eminent company in consulting and engineering for the pharmaceutical and chemical business in Europe. TTP’s portfolio includes a large length of engineering services and products, from feasibility research, ordinary and crystal clear engineering, to building control, in addition to commissioning, qualification, and validation services and products. Exyte and the monetary investor Robus Capital in conjunction with minority shareholders of TTP have signed the respective particular commitments. The acquisition value has been indubitably to stay undercover. The transaction is topic to the important regulatory approvals.

TTP is a specialised and a relied on spouse for blue-chip shoppers within the biotech, pharma and chemical industries in Europe. The corporate, via its two operational manufacturers ‘Pharmaplan’ and ‘Triplan,’ covers all of the carrier spectrum from Engineering to Procurement, Development Control, and Validation. Exyte will mix TTP’s operations with its personal Biopharma and Month Sciences actions in Europe. The purpose is to develop a powerful spouse for the booming Eu biotechnology and pharmaceutical business.

TTP executes quite a few initiatives, starting from revamps of present vegetation to the conclusion of occasion vegetation. The corporate has a strategic footprint in Europe and maintains a community of 27 places in Austria, Belgium, France, Germany, and Switzerland. In 2023, about 1,000 workers^[1] generated gross sales of a few €170 million. Within the coming years, TTP intends to proceed the robust successful enlargement of new years.

“By combining TTP’s engineering expertise with Exyte’s project execution capabilities, we will establish a robust presence in the biotech and pharma sector in Europe. This will enable us to offer clients the full range of collaboration, from strategic planning to the delivery of biotechnology and pharma facilities. With the planned acquisition, Exyte expands its position as a global player in the pharma market, strengthening its footprint in Europe. TTP’s employees are experienced and specialized experts, including engineers, architects, and project managers. Their expertise and innovative spirit will make a significant contribution to Exyte’s sustainable, profitable growth. We look forward to welcoming them soon to the Exyte team,” says Dr. Wolfgang Büchele, CEO of Exyte.

“TTP and Exyte share the same values and the ambition to offer innovative and sustainable solutions to their customers. Together, we will continue our growth trajectory in the booming pharmaceutical facilities market. The combination of our strengths is a positive signal for our customers. We look forward to a shared future with Exyte,” says Dr. Andreas Bonhoff, CEO of the TTP Team.

Investments in amenities because of megatrends and technological developments

Investments in manufacturing amenities within the pharmaceutical sector are anticipated to proceed to be on one?s feet within the coming years. Crowd enlargement and getting old supremacy to expanding calls for for scientific ingredients and merchandise. As well as, technical inventions similar to mRNA era and the securing of provide chains require brandnew and supplementary production capacities. Investments in present and brandnew amenities also are important because of expanding sustainability necessities. Snip time-to-market, flexibility, and virtual answers are central components within the engineering and building of brandnew amenities.

“The pharmaceutical industry, in particular, is facing exciting times ahead. Companies have many promising prospects on the horizon, with groundbreaking cell and gene therapies becoming increasingly available. With the acquisition of TTP, Exyte strengthens its presence in Europe. Together we will deliver sustainable high-tech facilities to improve the health and wellbeing of the world’s population,” says Ronan Donohue, President of Exyte’s World Industry Unit Biopharma and Month Sciences.

Strategic growth of Biopharma and Month Sciences

The World Industry Unit Biopharma and Month Sciences is the second-largest department of Exyte through gross sales. Income of Biopharma and Month Sciences reached €580 million in 2023. The form consumption grew through 12 p.c to €650 million. As a part of the “Next Level” schedule, the department’s income is predicted to proceed rising, with its proportion of overall gross sales expanding additional. Within the medium time period, Exyte’s industry department Biopharma and Month Sciences plans to reach greater than €1.5 billion in income. Lately, Exyte finished the quickest greenfield drug substance amenities ever constructed. Not up to 22 months handed from the beginning of thought design to the validation of the primary manufacturing layout in a mRNA competence middle in Germany.

About Exyte

Exyte is an international chief within the design, engineering, and supply of ultra-clean and sustainable amenities for high-tech industries. With state-of-the-art experience evolved over greater than a century, the corporate serves shoppers within the subtle markets of semiconductors, battery cells, prescribed drugs, biotechnology, and knowledge facilities. Exyte trade in a complete length of services and products from consulting to managing the implementation of constructed entire answers with the very best requirements in protection and attribute to its consumers international. Exyte creates a greater occasion through enabling key industries to fortify the attribute of recent week. In 2023, the corporate generated gross sales of €7.1 billion with round 9,900 workers international. www.exyte.net 

About TTP

TTP Team is a company workforce that specialize in consulting and engineering services and products for the method business. With greater than 1,000 workers operating underneath the operational manufacturers Pharmaplan and Triplan, the corporate operates at 27 places in Belgium, Germany, France, Austria, and Switzerland. Pharmaplan covers all of the price chain of pharmaceutical engineering, from consulting to the execution of EPCM initiatives and upgrades, qualification and validation in addition to native website help. Triplan, as a eminent engineering spouse for the chemical business, supplies the technical building of brandnew building, renovation initiatives, and the optimization of present amenities. With its two robust manufacturers, established for over 50 years, the TTP Team is thought of as some of the eminent engineering carrier suppliers in Europe. www.ttp-group.eu

^1. Complete Life Identical (FTE).

Photograph: https://mma.prnewswire.com/media/2496453/Exyte.jpg
Brand: https://mma.prnewswire.com/media/1487100/Exyte_Logo.jpg

Touch:
Samy Abdel Aal
People Members of the family Supervisor
Telephone: +49 711 88044696
Cellular: +49 172 840 33 01
[email protected]
www.exyte.net 

SOURCE Exyte